Reading the tape
NASDAQ: CVKD
Cadrenal Therapeutics, Inc. Common Stock
Healthcare · Biotechnology
Market Cap
$16.57M
52w High
$16.50
52w Low
$4.21
P/E
-1.00
Volume
56.47K
Outstanding Shares
2.51M
Price vs Fundamentals
Why The Stock Is Moving
Likely fundamental deteriorationModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -59.55%FCF (TTM): -71.19%
What changed
The stock fell 59.55% over the last year. Free cash flow declined 71.19% over the trailing twelve months.
What the market seems to be pricing
The market appears to be responding to weaker operating momentum rather than only rerating the stock.
What would invalidate this read
Free cash flow fell 71.19% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Company profile
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company.
CEOQuang X. Pham
SectorHealthcare
IndustryBiotechnology
Employees4
IPO dateJan 20, 2023
Valuation
Forward P/E—
EV/EBITDA-0.71
Enterprise value$9.51M
Stock splits
Aug 20, 2024↓ Reverse
Every 15 shares became 1
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-483.34%▼237.59%vs FY2024
Analyst consensus
RatingBuy
Target price$32.00▲384.11%
1
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$1.51 · Revenue est —
View